Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.48 |
| ▸ | PNP | P00491 | 2/20 | 0.47 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.47 |
| ▸ | KRAS | P01116 | 4/20 | 0.44 |
| ▸ | POLG | P54098 | 1/20 | 0.44 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401417 | 0.93 | TGM2 (0.53) | NT5EPOLBIMPDH2TGM2TAS1R3 | |
| SCHEMBL2826609 | 0.89 | NT5E (0.53) | NT5EPOLBIMPDH2TGM2TAS1R3 | |
| SCHEMBL14659959 | 0.87 | NT5E (0.51) | NT5EPOLBIMPDH2TGM2TAS1R3 | |
| SCHEMBL29093615 | 0.85 | NT5E (0.52) | NT5EPOLBIMPDH2TGM2TAS1R3 | |
| SCHEMBL3018983 | 0.85 | ADORA3 (0.47) | NT5EPNP | |
| SCHEMBL21105384 | 0.84 | POLB (0.53) | NT5EPOLBIMPDH2TGM2TAS1R3 | |
| SCHEMBL31448234 | 0.84 | POLB (0.51) | NT5EPOLBIMPDH2TGM2TAS1R3 | |
| SCHEMBL30984597 | 0.83 | NT5E (0.48) | NT5EPOLBIMPDH2TGM2TAS1R3 | |
| SCHEMBL29408561 | 0.83 | NT5E (0.43) | NT5EPOLBPNPPOLG | |
| SCHEMBL28993983 | 0.83 | NT5E (0.47) | NT5EPOLBIMPDH2TGM2TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122505-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | BANK OF AMERICA, N.A. | 2025-04-17 | — | — | US | disclosed |
| US-20230026968-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-01-26 | — | — | US | disclosed |
| EP-1907590-B1 | T7 RNA POLYMERASE AND METHODS FOR THE GENERATION OF FULLY 2'-MODIFIED NUCLEIC ACID TRANSCRIPTS | ARCHEMIX LLC (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2207891-B1 | MATERIALS AND METHODS FOR THE GENERATION OF TRANSCRIPTS COMPRISING MODIFIED NUCLEOTIDES | ARCHEMIX LLC (US) | 2012-07-25 | — | — | EP | disclosed |
| US-8105813-B2 | Materials and methods for the generation of fully 2′-modified nucleic acid transcripts | ARCHEMIX CORP. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8101385-B2 | Materials and methods for the generation of transcripts comprising modified nucleotides | ARCHEMIX CORP. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2207891-A2 | MATERIALS AND METHODS FOR THE GENERATION OF TRANSCRIPTS COMPRISING MODIFIED NUCLEOTIDES | Archemix Corp. (US) | 2010-07-21 | — | — | EP | disclosed |
| US-20100120024-A1 | Materials and methods for the generation of transcripts comprising modified nucleotides | ARCHEMIX CORP. | 2010-05-13 | — | — | US | disclosed |
| WO-2008078180-A2 | MATERIALS AND METHODS FOR THE GENERATION OF TRANSCRIPTS COMPRISING MODIFIED NUCLEOTIDES | ARCHEMIX CORP. (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1907590-A2 | MATERIALS AND METHODS FOR THE GENERATION OF FULLY 2'-MODIFIED NUCLEIC ACID TRANSCRIPTS | Archemix Corp. (US) | 2008-04-09 | — | — | EP | disclosed |
| US-20070117112-A1 | Materials and methods for the generation of fully 2'-modified nucleic acid transcripts | ARCHEMIX CORP. | 2007-05-24 | — | — | US | disclosed |
| WO-2007005645-A2 | MATERIALS AND METHODS FOR THE GENERATION OF FULLY 2'-MODIFIED NUCLEIC ACID TRANSCRIPTS | ARCHEMIX CORP. (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026968-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | AARS1, RNASE1, DDX39B | NT5E 2411/4885POLB 755/4885IMPDH2 758/4885 |
| US-20250122505-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | AARS1, RNASE1, DDX39B | NT5E 2411/4885POLB 755/4885IMPDH2 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.